Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy
- 作者: Ardatskaya M.1, Butorova L.2, Kalashnikova M.3, Nugaeva N.1, Ovchinnikov Y.1, Oynotkinova O.4,5, Pavlov A.6, Plavnik R.7, Sayutina E.8, Topchiy T.2, Trunova S.9
-
隶属关系:
- Branch of Kirov Military Medical Academy
- Central State Medical Academy of the President of the Russian Federation
- Central Clinical Hospital for Rehabilitation Treatment of the President of the Russian Federation
- Lomonosov Moscow State University
- Research Institute for Healthcare Organization and Medical Management
- Vishnevsky 3rd Central Military Clinical Hospital
- ISOCARB LLC
- Yevdokimov Moscow State University of Medicine and Dentistry
- Clinic “K+31”
- 期: 卷 93, 编号 8 (2021)
- 页面: 923-931
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/79522
- DOI: https://doi.org/10.26442/00403660.2021.08.201020
- ID: 79522
如何引用文章
全文:
详细
Background. The novel coronavirus infection COVID-19 can be manifested by damage to the organs of the gastrointestinal tract (GIT). Damage to the gastrointestinal tract by the SARS-CoV-2 virus leads to a violation of the microbial-tissue complex of the mucous membrane of the digestive tract. A common gastroenterological manifestation of COVID-19 is diarrhea.
Aim. Study of the clinical features of gastroenterological disorders and the possibility of optimizing the treatment of diarrheal syndrome in patients with COVID-19 with a mild form of viral infection.
Materials and methods. The observation group consisted of 230 patients with mild COVID-19: K-group (n=115) – with respiratory symptoms, I group (n=115) – with gastrointestinal manifestations in combination and without signs of respiratory damage. In order to compare the effectiveness of treatment of diarrheal syndrome, patients of group I are randomized into 2 subgroups: Ia (n=58) – prebiotic treatment (Zacofalk®) and Ib (n=57) – enterosorbents.
Results. The development of gastrointestinal symptoms with SARS-CoV-2 infection is significantly more often noted in comorbid patients (67%). Gastrointestinal symptoms were dominated by diarrhea (93.9%) and flatulence (76.5%), in 1/3 of patients they were the first manifestos of infection. It was established that in 98.4% of patients of group I (against 42.6% of the K-group) signs of infectious intoxication were detected. In patients with gastrointestinal lesions, an elongation of the febrile period by 9±1.5 days was noted, a later (6 days) verification of the viral etiology of the disease. It was found that in patients of group I, the regression of clinical symptoms, the duration of viral disease, the dynamics of antibody formation, the prognosis for the development of IBS-like disorders in the post-infectious period depended on the treatment. In patients taking (Zacofalk®), these indicators were significantly better.
Conclusion. In mild cases, to reduce the severity of viral intestinal damage, for effective relief of intestinal symptoms, to reduce the risk of IBS-like symptoms, it is advisable to prescribe (Zacofalk®) in an initial dose of 3 tablets per day.
作者简介
Maria Ardatskaya
Branch of Kirov Military Medical Academy
Email: ludmilabutorova@mail.ru
ORCID iD: 0000-0001-8150-307X
доктор медицинских наук, профессор каф. гастроэнтерологии
俄罗斯联邦, MoscowLudmila Butorova
Central State Medical Academy of the President of the Russian Federation
编辑信件的主要联系方式.
Email: ludmilabutorova@mail.ru
ORCID iD: 0000-0003-4689-2844
кандидат медицинских наук, преподаватель каф. терапии неотложных состояний филиала
俄罗斯联邦, MoscowMarina Kalashnikova
Central Clinical Hospital for Rehabilitation Treatment of the President of the Russian Federation
Email: ludmilabutorova@mail.ru
ORCID iD: 0000-0003-2606-198X
врач-гастроэнтеролог
俄罗斯联邦, MoscowNelli Nugaeva
Branch of Kirov Military Medical Academy
Email: ludmilabutorova@mail.ru
ORCID iD: 0000-0002-1938-7829
кандидат медицинских наук, преподаватель кафедры терапии неотложных состояний филиала
俄罗斯联邦, MoscowYury Ovchinnikov
Branch of Kirov Military Medical Academy
Email: ludmilabutorova@mail.ru
ORCID iD: 0000-0003-1843-087X
доктор медицинских наук, доцент, начальник каф. терапии неотложных состояний филиала
俄罗斯联邦, MoscowOlga Oynotkinova
Lomonosov Moscow State University; Research Institute for Healthcare Organization and Medical Management
Email: ludmilabutorova@mail.ru
ORCID iD: 0000-0002-9856-8643
доктор медицинских наук, профессор, профессор каф. факультета фундаментальной медицины, начальник отд. ГБУ НИИОЗММ
俄罗斯联邦, Moscow; MoscowAleksandr Pavlov
Vishnevsky 3rd Central Military Clinical Hospital
Email: ludmilabutorova@mail.ru
ORCID iD: 0000-0003-1836-7946
доктор медицинских наук, доцент, начальник Центра гастроэнтрологии и гепатологии
俄罗斯联邦, KrasnogorskRoman Plavnik
ISOCARB LLC
Email: ludmilabutorova@mail.ru
ORCID iD: 0000-0001-5448-8812
кандидат медицинских наук, зам. ген. директора по науке и внедрению
俄罗斯联邦, MoscowElena Sayutina
Yevdokimov Moscow State University of Medicine and Dentistry
Email: ludmilabutorova@mail.ru
ORCID iD: 0000-0001-9611-5096
доцент кафедры терапии, клинической фармакологии и скорой медицинской помощи
俄罗斯联邦, MoscowTatiana Topchiy
Central State Medical Academy of the President of the Russian Federation
Email: ludmilabutorova@mail.ru
ORCID iD: 0000-0003-4491-881X
кандидат медицинских наук, доцент кафедры гастроэнтерологии
俄罗斯联邦, MoscowSvetlana Trunova
Clinic “K+31”
Email: ludmilabutorova@mail.ru
ORCID iD: 0000-0001-9523-9820
врач-гастроэнтеролог клиники
俄罗斯联邦, Moscow参考
- Ивашкин В.Т., Шептулин А.А., Зольникова О.Ю., и др. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения. Российский журн. гастроэнтерологии, гепатологии, колопроктологии. 2020;30(2):7-13 [Ivashkin VT, Sheptulin AA, Zolnikova OYu, et al. New Coronavirus Infection (COVID-19) and Digestive System. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):7-13 (in Russian)]. doi: 10.22416/1382-4376-2020-30-3-7
- Zarifian A, Bidary MZ, Arekhi S, et al. Gastrointestinal and hepatic abnormalities in patients with confirmed COVID-19: a systematic review and meta-analysis. J Med Virol. 2020. doi: 10.1002/jmv.26314.doi:10.1002/jmv.26314
- Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020.158(6):1518-9. doi: 10.1053/j.gastro.2020.02.054
- Saleh J, Peyssonnaux C, Singh KK, Edeas M. Mitochondria and microbiota dysfunction in COVID-19 pathogenesis. Mitochondrion. 2020;54:1-7. doi: 10.1016/j.mito.2020.06.008
- Zuo T, Zhang F, Lui GCY, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020;159(3):944-955.e8. doi: 10.1053/j.gastro.2020.05.048
- Tang L, Gu S, Gong Y, et al. Clinical significance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity. Engineering. 2020. doi: 10.1016/j.eng.2020.05.013
- Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 3 (03.03.20) [Temporary methodical recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 3 (03.03.20) (in Russian)].
- Гриневич В.Б., Губонина И.В., Дощицин В.Л., и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020;19(4):2630 [Grinevich VB, Gubonina IV, Doshchitsin VL, et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular therapy and prevention. 2020;19(4):2630 (in Russian)]. doi: 10.15829/1728-8800-2020-2630
- Бахарев С.Д., Бауло Е.В., Быкова С.В., и др. COVID-19 и тонкая кишка. Терапевтический архив. 2021;93(3):343-7 [Bakharev SD, Baulo EV, Bykova SV, et al. COVID-19 and the small intestine. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(3):343-7 (in Russian)]. doi: 10.26442/00403660.2021.03.200662
- Li J, Richards EM, Handberg EM, et al. Butyrate Regulates COVID-19-Relevant Genes in Gut Epithelial Organoids From Normotensive Rats. Hypertension. 2021;77(2):e13-e16. doi: 10.1161/HYPERTENSIONAHA.120.16647